Although the combination of PD-1 blockades and lenvatinib has shown promising clinical responses as a first-line therapy for advanced or recurrent endometrial cancer [166], LEAP-08 and LEAP-10 did not show clinical benefits in lung cancer and head and neck cancer, respectively. This evidence concerns the gene PDCD1 and lung cancer.